Research Intelligence
Domain intelligence and research briefings demonstrating the editorial authority OrganLabs.com delivers to its acquirer — the natural home for cutting-edge coverage of artificial organs, bioprinting and regenerative medicine.
Lead Research
Cover Analysis · 3D Bioprinting · Clinical Translation
The organ shortage crisis kills 17 Americans every day. The 3D bioprinting revolution is moving faster than almost anyone predicted. In 2022, a human patient received the first 3D-printed ear implant — a milestone that would have seemed impossible fifteen years ago. Now, researchers are closing in on the vascularisation problem that separates printed tissue from printed organs. The decade ahead will determine whether bioprinting becomes the technology that ends the organ shortage crisis.
Read Full Research →Artificial Organs
Organ-on-Chip
Domain Intelligence
All Research Articles
Regenerative Medicine
The UCSF-led Kidney Project is combining silicon nanopore membranes with living tubule cells to create a device that could end dialysis for 800,000 Americans.
Stem Cells
By reprogramming a patient's own skin cells into pluripotent stem cells, researchers can now grow the patient's own heart muscle, liver cells or retinal tissue in the lab.
Vascularisation
Every organ above a certain thickness needs a blood supply network. Building functional blood vessels into bioprinted tissue is the hardest unsolved problem in organ fabrication — and the teams closest to solving it.
Xenotransplantation
CRISPR-edited pig kidneys have functioned in brain-dead human recipients and briefly in a living patient. Whether xenotransplantation is a bridge or an endpoint depends on answers still being written in labs.
AI in Bioprinting
AI models are optimising bio-ink rheology, predicting cell viability post-print, designing vascular networks and planning patient-specific implant geometry — compressing years of iteration into weeks.
Health Policy
The landmark US legislation explicitly permits non-animal testing alternatives — including organ-on-chip and bioprinted tissue models — in FDA submissions. A transformative moment for the entire organ technology industry.
The Media Opportunity
The articles above represent a fraction of the editorial agenda available to OrganLabs.com. The organ technology field — spanning 3D bioprinting, artificial organs, organ-on-chip, xenotransplantation, stem cell therapy and AI-assisted organ engineering — is one of the most dynamic, consequential and underserved niches in science journalism.
Nature Medicine, STAT News and The Atlantic cover this field episodically. OrganLabs.com is the name for the publication — or the company — that covers it comprehensively, daily and with the depth that scientists, clinicians, investors and patients deserve.
Acquire OrganLabs.com →Research Audience
● Editorial authority from day one — available for acquisition ●